OOIR: Observatory of International Research

Papers

(The H4-Index of Value in Health is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
HPR6 Beyond Conventional Clinical Value: Estimating the Impact of Accelerated Approvals on Therapeutic Bridging between Innovative Therapies	461
PNS48 Do US Commercial Health Plans Cite ICER Reports in Their Specialty Drug Coverage Policies? an Empirical Analysis	454
Editorial Board	87
HPR25 Patient Organisations' Submissions to the Pharmaceutical Pricing Board in Finland	75
Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare	74
Table of Contents	69
Editorial Board	65
Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact	65
HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?	63
EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective	54
MSR47 Feasibility Assessment of Indirect Treatment Comparison of Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps	54
HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany	52
HSD35 If Primary Prevention Is the Solution, Why Don't We Take Advantage of All Opportunities in Brazil?	50
POSB179 Epidemiological Disease Burden of Heart Failure, Unspecified Based on Routinely Collected Health Insurance Claims Data	47
EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK	47
HPR146 Specialty Pharmacy Use and Adherence to Oral Anticancer Medications for Breast Cancer and Prostate Cancer: Implications for Medicare Part D Policy	46
POSC176 Is Pain Severity Associated with Functional Limitations Among United States Adults? A Cross-Sectional Study Using 2018 Medical Expenditure Panel Survey	44
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	43
HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review	42
PCR11 Understanding the Patient Experience of Erythropoietic Protoporphyria and X-Linked Protoporphyria: A Qualitative Study	41
POSC173 The Association Between Physical Activity, Body Mass Index and Health Complaints Among Hungarian School-Aged Children	41
POSB213 Assessing the Changes of Hungarian Health Professional Workforce, Proportional to Population between 2003-2018	38
HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment	38
MSR93 A Systematic Review of Current Evidence and Gaps on the Impact of Oral Antipsychotic Treatments in Schizophrenia	38
SA60 Seeking ISPOR Abstracts: Is Searching Embase Enough?	36

POSB187 Study of Awareness of Pharmacy Employees in Ukraine with the Problem of Antibiotics Resistance	35
EE198 Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Essential Hypertension in Chinese Setting	35
PCR68 Patient-Provider Communication and Health-Related Quality of Life Among Individuals with Chronic Obstructive Pulmonary Disease in the United States	34
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib	34
EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan	33
EE279 A Systematic Literature Review of the Economic Burden in Patients with Myelodysplastic Syndrome	33
MSR33 Application and Feasibility of Indirect Treatment Comparison of Switch Maintenance and Non-Maintenance Oncology Regimens to Inform HTA Decision-Making	32
PCR101 Item Response Theory Analysis of the Ilqi	32
CO66 Real-World Study on Characteristics, Post-Nephrectomy Journey, and Outcomes of Patients with Early-Stage Renal Cell Carcinoma Based on Risk Groups	32
MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods	32